What You Should Know
- A new treatment combination, darovasertib plus crizotinib, helped patients with metastatic uveal melanoma stay in remission more than twice as long as current options, which is a major step forward for people who previously had no approved treatments.
- About 60% of patients with advanced uveal melanoma are not eligible for the only existing therapy, and the phase 3 OptimUM-02 trial offers the first real hope of an effective frontline option for them.
- Side effects were mostly manageable, and early results suggest this treatment could become an important new choice for many patients, including those who may need options after tebentafusp.
Among the most practice-changing melanoma presentations at ASCO 2026 was the late-breaking phase 3 OptimUM-02 trial evaluating darovasertib plus crizotinib in metastatic uveal melanoma.
The study met its primary endpoint of PFS, potentially establishing the first FDA-approved frontline systemic therapy for patients with HLA-A*02:01-negative metastatic uveal melanoma, a population with no approved treatment options.
“Uveal melanoma behaves much more aggressively,” said Dr. Igor Puzanov, chief of melanoma and skin cancer services at Roswell Park Comprehensive Cancer Institute.
“Besides tebentafusp for patients whose HLA type is A*02:01, we don’t have any approved treatments by the FDA whatsoever. However, this is hopefully going to change.”
What Does the Data Say
OptimUM-02 demonstrated a median progression-free survival (PFS) of 6.9 months with darovasertib plus crizotinib compared with 3.1 months for investigator’s choice therapy, which primarily consisted of checkpoint inhibitors such as ipilimumab plus nivolumab.
The objective response rate was 37% versus 6% in the control arm. Overall survival (OS) data remain immature but are trending favorably.
“The PFS endpoint has been met,” Dr. Puzanov noted. “That’s both clinically and statistically significant improvement.”
The significance of the findings extends beyond efficacy. While tebentafusp has transformed outcomes for HLA-A*02:01-positive patients, approximately 60% of patients lack this HLA subtype and remain without an approved standard-of-care systemic therapy.
“That 60% didn’t have anything approved for them until now,” Dr. Puzanov said. “This is actually a real breakthrough because there was nothing approved to be used.”
The regimen combines darovasertib, a protein kinase C inhibitor, with the MET inhibitor crizotinib. Although crizotinib is well established in NSCLC, its use in uveal melanoma represents a successful drug repurposing strategy.
“Crizotinib is really repurposed here,” Dr. Puzanov explained. “It’s already serving other purposes and now finding a new purpose in patients who didn’t have any options before.”
The data may also have sequencing implications beyond the HLA-A02:01-negative population.
Early studies have suggested activity across HLA subgroups, raising the possibility that this combination could emerge as a treatment option for HLA-A02:01-positive patients following tebentafusp.
“Not only will this drug provide a first hope in those HLA-A02:01-negative patients, but also provide a backup or alternative to patients with HLA-A02:01-positive blood type,” Dr. Puzanov said.
A Meaningful Advancement
Gastrointestinal toxicities, including nausea, vomiting, and diarrhea, were the primary management considerations.
“These drugs are pills, and doctors are very good at prescribing pills and managing side effects,” Dr. Puzanov said.
After decades of largely unsuccessful efforts with MEK inhibitors, checkpoint inhibitors, and other targeted approaches, OptimUM-02 represents one of the most meaningful advances yet in metastatic uveal melanoma.
“The first breakthrough was tebentafusp, and now the second breakthrough is coming as darovasertib plus crizotinib,” Dr. Puzanov said.
If the PFS benefit ultimately translates into improved long-term outcomes and gains regulatory approval, OptimUM-02 could fundamentally alter the treatment paradigm for metastatic uveal melanoma and provide the first broadly applicable systemic option for a disease long defined by limited therapeutic progress.
